Robert A. Verhagen

ImmunoBiochem Corp. is a biopharmaceutical company founded in 2007, based in Canada. The private company is focused on developing biological therapeutics to address unmet needs in oncology and immuno-oncology. ImmunoBiochem has worked closely with the University of Toronto, one of the world's leading institutions in research and innovation, on some of its novel programs. The Canadian company uses high-throughput functional screens, bioinformatics, and AI/ML to discover novel tumor targets in the tumor microenvironment, particularly in the cancer cell secretome. The company is a Johnson & Johnson Innovation JLABS alumnus and is headquartered in the heart of Canada's largest biomedical research hub.

ImmunoBiochem Corp. is a biopharmaceutical company founded in 2007, based in Canada. The private company is focused on developing biological therapeutics to address unmet needs in oncology and immuno-oncology. ImmunoBiochem has worked closely with the University of Toronto, one of the world's leading institutions in research and innovation, on some of its novel programs. The Canadian company uses high-throughput functional screens, bioinformatics, and AI/ML to discover novel tumor targets in the tumor microenvironment, particularly in the cancer cell secretome. The company is a Johnson & Johnson Innovation JLABS alumnus and is headquartered in the heart of Canada's largest biomedical research hub.